Nimenrix
meningococcal group A, C, W 135 and Y conjugate vaccine
Table of contents
Overview
Nimenrix is a vaccine used to protect adults, adolescents and children from the age of 6 weeks against invasive meningococcal disease caused by four groups of the bacterium Neisseria meningitidis (group A, C, W-135, and Y). Invasive disease occurs when the bacteria spread through the body causing serious infections such as meningitis (infection of the membranes that surround the brain and spine) and septicaemia (blood poisoning).
The vaccine contains substances from the outer coat of the bacterium N. meningitidis.
Authorisation details
Product details | |
---|---|
Name |
Nimenrix
|
Agency product number |
EMEA/H/C/002226
|
Active substance |
|
International non-proprietary name (INN) or common name |
meningococcal group A, C, W 135 and Y conjugate vaccine
|
Therapeutic area (MeSH) |
Meningitis, Meningococcal
|
Anatomical therapeutic chemical (ATC) code |
J07AH08
|
Publication details | |
---|---|
Marketing-authorisation holder |
Pfizer Europe MA EEIG
|
Revision |
31
|
Date of issue of marketing authorisation valid throughout the European Union |
20/04/2012
|
Contact address |
Product information
03/11/2020 Nimenrix - EMEA/H/C/002226 - IB/0104
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Vaccines
Therapeutic indication
Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal diseases caused by Neisseria meningitidis group A, C, W-135, and Y.